Invention Grant
- Patent Title: Glucuronide prodrugs of Janus kinase inhibitors
-
Application No.: US15986028Application Date: 2018-05-22
-
Publication No.: US10745405B2Publication Date: 2020-08-18
- Inventor: Daniel D. Long , Donna A. A. Wilton , Mandy M. Loo , Ryan Hudson , Patrick J. Brassil
- Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
- Applicant Address: US CA South San Francisco
- Assignee: Theravance Biopharma R&D IP, LLC
- Current Assignee: Theravance Biopharma R&D IP, LLC
- Current Assignee Address: US CA South San Francisco
- Agent Jeffrey A. Hagenah; Florence Jovic
- Main IPC: C07D487/04
- IPC: C07D487/04 ; A61P29/00 ; C07H17/02 ; C07H15/26 ; C07H1/00 ; C07H13/12
Abstract:
The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula I: where W1, R1 and A1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
Public/Granted literature
- US20180339990A1 GLUCURONIDE PRODRUGS OF JANUS KINASE INHIBITORS Public/Granted day:2018-11-29
Information query
